Sign in

CIK 0001677077

  • Emerging growth company

Alzamend Neuro, Inc.

Sign in to watch
Ticker
ALZN
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
FY end
Apr 30
Incorporated
DE
Entity type
Operating
EIN
811822909
Phone
+1 844-722-6333
Business address
480 PEACHTREE ROAD NE, SECOND FLOOR, SUITE 103, ATLANTA, GA, 30326
  1. 4 Open-market sale Director sold 25,000 shares at $1.21 ($30,325)
  2. 4 Open-market sale Director sold 20,000 shares at $1.21 ($24,202)
  3. 4 Open-market buy 10% owner bought 100,000 shares at $1.10 ($110,450)
  4. 4 Exercise or conversion Director acquired 50,000 shares (option exercise)
  5. 4 Exercise or conversion Director acquired 50,000 shares (option exercise)
  6. 4 Exercise or conversion Director acquired 50,000 shares (option exercise)
  7. 4 Exercise or conversion Director acquired 50,000 shares (option exercise)
  8. 4 Other disposition 10% owner disposed of 57,016 shares (other)
  9. 4 Open-market buy 10% owner bought 22,500 shares at $1.15 ($25,961)
  10. 4 Exercise or conversion 10% owner acquired 2,250,000 shares (option exercise)
  11. 4 Open-market buy 10% owner bought 2,500 shares at $1.40 ($3,488)
  12. 4 Open-market buy 10% owner bought 5,000 shares at $1.29 ($6,450)
  13. 4 Exercise or conversion Director acquired 150,000 shares (option exercise)
  14. 4 Open-market buy 10% owner bought 7,000 shares at $1.66 ($11,619)
  15. 4 Open-market buy 10% owner bought 3,000 shares at $1.79 ($5,368)
  16. 4 Open-market buy 10% owner bought 3,000 shares at $1.93 ($5,775)
  17. 4 Open-market buy 10% owner bought 2,000 shares at $1.98 ($3,959)
  18. 4 Open-market buy 10% owner bought 8,000 shares at $1.91 ($15,290)
  19. 4 Open-market buy 10% owner bought 1,612 shares at $2.10 ($3,377)
  20. 4 Open-market buy 10% owner bought 38,000 shares at an average $2.24 ($84,969)

Page 6 of 9 · 170 filings